Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
By P. Moreau, T. Masszi, N. Grząśko, N. Bahlis, M. Hansson, L. Pour, I. Sandhu, P. Ganly, B. Baker, S. Jackson and 16 more. New England Journal of Medicine, 2016
974 citations recorded by the source corpus.
Subfields: Hematology, Molecular Biology, Plant Science
View Paper: https://www.semanticscholar.org/paper/41ad797a130c75d61f9e714e6a064eaea6d8f85d
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hematology
In Molecular Biology
Citations in the corpus
- Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management (2020, background): “In a randomized controlled trial in relapsed multiple myeloma, ixazomib, lenalidomide, dexamethasone (IRd) was found to improve PFS compared with Rd (Table 8).(72) Based on these results ixazomib was initially approved by the FDA in 2015 to be given in combination with Rd for the treatment of patien”
- Multiple myeloma: 2022 update on diagnosis, risk stratification, and management (2022, background): “Ixazomib is an oral proteasome inhibitor that is active in both the relapsed refractory setting and in newly diagnosed multiple myeloma.(71,159) It has the advantage of once-weekly oral administration.”